APPLICATION
ANDA202338
TYPE
ANDA
ORIGINAL APPROVAL
2013-06-28
LATEST ACTION
2025-06-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued
Products
IMIPRAMINE PAMOATEDiscontinued
IMIPRAMINE PAMOATE EQ 150MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEDiscontinued
IMIPRAMINE PAMOATE EQ 100MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEDiscontinued
IMIPRAMINE PAMOATE EQ 125MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEDiscontinued
IMIPRAMINE PAMOATE EQ 75MG HYDROCHLORIDE · CAPSULE · ORAL
Approval history
2025-06-24Labeling · Supplement 4 · standardAP
2020-04-27Labeling · Supplement 2 · standardAP
2013-06-28OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.